• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[急性冠状动脉综合征与介入治疗中的血小板活化]

[Platelet activation in acute coronary syndrome and interventional therapy].

作者信息

Bigalke B, Lindemann S, Gawaz M

机构信息

Medizinische Klinik III, Eberhard Karls Universität Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen.

出版信息

Hamostaseologie. 2007 Dec;27(5):338-43.

PMID:18060243
Abstract

Platelets play a critical role in formation of coronary thrombosis. An enhanced systemic platelet activation plays a significant role in the acute coronary syndrome. Despite better interventional techniques and better concomitant pharmacological therapy, the degree of platelet activation contributes significantly to prognosis and postinterventional event rate. Residual platelet activation after intervention is often associated with an enhanced initial platelet activation prior interventional treatment. An effective antiplatelet therapy is of utmost importance for the acute therapy and for secondary prevention in patients undergoing coronary interventions or with acute coronary syndrome. The efficacy of the antithrombotic therapy determines the long term prognosis in these patients.

摘要

血小板在冠状动脉血栓形成中起关键作用。全身性血小板活化增强在急性冠状动脉综合征中起重要作用。尽管有更好的介入技术和更有效的伴随药物治疗,但血小板活化程度对预后和介入后事件发生率仍有显著影响。介入后残留的血小板活化通常与介入治疗前初始血小板活化增强有关。有效的抗血小板治疗对于接受冠状动脉介入治疗或患有急性冠状动脉综合征的患者的急性治疗和二级预防至关重要。抗血栓治疗的疗效决定了这些患者的长期预后。

相似文献

1
[Platelet activation in acute coronary syndrome and interventional therapy].[急性冠状动脉综合征与介入治疗中的血小板活化]
Hamostaseologie. 2007 Dec;27(5):338-43.
2
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.经皮冠状动脉介入治疗:评估与裸金属支架和药物洗脱支架相关的冠状动脉血管风险。
Am J Manag Care. 2009 Mar;15(2 Suppl):S42-7.
3
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.抗血小板药物反应变异性及血小板功能检测的作用:介入心脏病学家实用指南
Catheter Cardiovasc Interv. 2009 Jan 1;73(1):1-14. doi: 10.1002/ccd.21782.
4
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.阿司匹林和氯吡格雷双联抗血小板治疗的适应证:基于证据的使用建议。
Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4.
5
Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.抗血小板治疗改善经皮冠状动脉介入治疗术后结局:解读当前关于急性冠状动脉综合征后患者优化管理的治疗指南。
Am J Manag Care. 2009 Mar;15(2 Suppl):S48-53.
6
Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.冠心病的抗血小板治疗。治疗和预防急性心肌梗死的新策略。
Arch Pathol Lab Med. 1993 Jan;117(1):89-96.
7
New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?新型抗血栓药物:它们是否必要,能为非ST段抬高型急性冠状动脉综合征患者带来什么?
Eur Heart J. 2009 Jul;30(14):1695-702. doi: 10.1093/eurheartj/ehp230. Epub 2009 Jun 1.
8
Platelet activation in myocardial ischemic syndromes.
Expert Rev Cardiovasc Ther. 2004 Jul;2(4):535-45. doi: 10.1586/14779072.2.4.535.
9
Antithrombotic treatment in acute coronary syndromes.急性冠脉综合征的抗血栓治疗。
Minerva Med. 2010 Aug;101(4):215-38.
10
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.普拉格雷对接受经皮冠状动脉介入治疗的急性冠脉综合征患者的早期和晚期获益:TRITON-TIMI 38(通过普拉格雷优化血小板抑制评估治疗转归改善的试验-心肌梗死溶栓38)分析
J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002.